Hilde Nilsen, University of Oslo, Arkershus University Hospital, Norway. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD +) and healthy aging research, shares results from a phase II clinical study published in the peer-reviewed journal, Movement Disorders, by a team of researchers led by Dr.
LOS ANGELES, November 15, 2023-( BUSINESS WIRE)- ChromaDex Corp. This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated
